Molecular Cancer

Papers
(The H4-Index of Molecular Cancer is 84. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression1082
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations651
Immunotherapies in rare cancers628
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments587
Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC566
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells444
Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance410
Crosstalk between N6-methyladenosine modification and circular RNAs: current understanding and future directions403
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6376
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway374
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer371
Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC357
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies350
Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer313
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade274
A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology274
The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway247
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes243
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells235
Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy226
LAMTOR1 decreased exosomal PD-L1 to enhance immunotherapy efficacy in non-small cell lung cancer212
Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets209
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors200
Targeting m7G-enriched circKDM1A prevents colorectal cancer progression194
Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications194
Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases193
PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation191
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia176
Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma174
A multidimensional recommendation framework for identifying biological targets to aid the diagnosis and treatment of liver metastasis in patients with colorectal cancer172
Chaperone-mediated autophagy modulates Snail protein stability: implications for breast cancer metastasis165
circNOX4 activates an inflammatory fibroblast niche to promote tumor growth and metastasis in NSCLC via FAP/IL-6 axis163
Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers159
A novel NF-κB regulator encoded by circPLCE1 inhibits colorectal carcinoma progression by promoting RPS3 ubiquitin-dependent degradation149
The senescence journey in cancer immunoediting142
CRISPR based therapeutics: a new paradigm in cancer precision medicine135
LINE-1 promotes tumorigenicity and exacerbates tumor progression via stimulating metabolism reprogramming in non-small cell lung cancer133
PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma132
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles132
Immunotherapy: an emerging modality to checkmate brain metastasis129
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes124
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers118
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma117
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome116
Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma116
Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program115
N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2115
Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies115
Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis114
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer114
Nanomedicines harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors111
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis111
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction110
The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells109
Unraveling the key role of chromatin structure in cancer development through epigenetic landscape characterization of oral cancer108
The cancer metabolic reprogramming and immune response108
Exosomal circSIPA1L3-mediated intercellular communication contributes to glucose metabolic reprogramming and progression of triple negative breast cancer107
Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis106
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial104
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine104
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers102
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis102
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?102
Mapping cancer biology in space: applications and perspectives on spatial omics for oncology102
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application101
LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter101
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities101
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research99
DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma99
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold99
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial97
CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer97
A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer96
CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid leukemia96
Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?93
Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy91
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery90
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo90
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy89
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy89
LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM89
Therapeutic challenges in peripheral T-cell lymphoma89
lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m6A reader YTHDC287
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition86
Cuproptosis: mechanisms and links with cancers84
Lung cancer immunotherapy: progress, pitfalls, and promises84
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches84
The function and mechanisms of action of circular RNAs in Urologic Cancer84
0.1305410861969